amvuttra (vutrisiran) injection 25 mg/0.5 mL

Join us for a presentation

Introduction to AMVUTTRA® (vutrisiran)

Please join your colleagues for a dynamic discussion about AMVUTTRA, sponsored by Alnylam Pharmaceuticals and presented by Dr. Malhotra, from Cook County Health, who will be joined by Gary, treated with AMVUTTRA.

Program details:
Thursday, April 25, 2024 6:30 PM EDT
Ocean Prime Detroit, 2915 Coolidge Hwy
Troy, MI 48084

Saurabh Malhotra, MD, MPH, Associate Professor & Director of Advanced Cardiac Imaging, Cook County Health
Dinner will be provided. To comply with PhRMA Code guidance, alcohol is not provided at Alnylam programs.

This program will cover:

- Overview of hereditary transthyretin-mediated (hATTR) amyloidosis
- AMVUTTRA mechanism of action
- AMVUTTRA clinical profile
- AMVUTTRA dosing & administration
- Overview of patient support program

For questions please contact:

Linda Warra at lwarra@alnylam.com or (734) 652-9899

Register Now!

https://alnylamevents.com/hcpevents?id=EM-03139 Or call 1-833-223-2204

This program is intended for US healthcare professionals only. Guests and spouses may not attend this program. Additionally, any meals offered in connection with this program may be reportable and publicly disclosed as required by the Physician Payments Sunshine Act and any applicable state laws. US healthcare professionals must provide their NPI and/or State License Number to register for the program. This is not an accredited education program, and no CME credits are offered.

Indication

AMVUTTRA® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Please see Important Safety Information on the next page and full Prescribing Information.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

For additional information about AMVUTTRA, please see the full Prescribing Information.

amvuttra® (vutrisiran) injection 25 mg/0.5 mL

Sign up to stay informed at

www.amvuttrahcp.com/sign-up